Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.35 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.35 |
| ▸ | PLG | P00747 | 1/20 | 0.34 |
| ▸ | PLAT | P00750 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL915025 | 1.00 | KMT2A (0.44) | KMT2ASMN1; SMN2ANPEPENPEPPLG | |
| SCHEMBL2973377 | 0.93 | KMT2A (0.43) | KMT2ASMN1; SMN2ANPEPENPEPPLG | |
| SCHEMBL2973379 | 0.93 | KMT2A (0.43) | KMT2ASMN1; SMN2ANPEPENPEPPLG | |
| SCHEMBL916757 | 0.90 | KMT2A (0.44) | KMT2ASMN1; SMN2ANPEPENPEPMEN1 | |
| SCHEMBL916759 | 0.90 | KMT2A (0.44) | KMT2ASMN1; SMN2ANPEPENPEPMEN1 | |
| SCHEMBL915845 | 0.90 | KMT2A (0.44) | KMT2ASMN1; SMN2ANPEPENPEPPLG | |
| SCHEMBL915843 | 0.90 | KMT2A (0.44) | KMT2ASMN1; SMN2ANPEPENPEPPLG | |
| SCHEMBL915722 | 0.90 | KMT2A (0.46) | KMT2ASMN1; SMN2ANPEPENPEPPLG | |
| SCHEMBL915724 | 0.90 | KMT2A (0.46) | KMT2ASMN1; SMN2ANPEPENPEPPLG | |
| SCHEMBL916298 | 0.88 | KMT2A (0.46) | KMT2ASMN1; SMN2ANPEPENPEPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101253148-B | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT INC | 2013-01-02 | — | — | CN | claimed |
| EP-1919859-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE | XENOPORT INC (US) | 2010-06-02 | — | — | EP | claimed |
| CN-101253148-A | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT INC (US) | 2008-08-27 | — | — | CN | claimed |
| US-7351740-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2008-04-01 | — | — | US | claimed |
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. | 2007-02-01 | — | — | US | claimed |
| US-8372881-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| CN-101253148-B | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT INC | 2013-01-02 | — | — | CN | disclosed |
| US-20110060040-A1 | USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID | XENOPORT, INC. | 2011-03-10 | — | — | US | disclosed |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-7777070-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| EP-1919859-B1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID AND USE | XENOPORT INC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20100036148-A1 | Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use | XENOPORT, INC. (US) | 2010-02-11 | — | — | US | disclosed |
| US-7592369-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| CN-101253148-A | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT INC (US) | 2008-08-27 | — | — | CN | disclosed |
| US-20080153898-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | XENOPORT, INC. | 2008-06-26 | — | — | US | disclosed |
| US-7351740-B2 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | XENOPORT, INC. | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060040-A1 | USES OF ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID | PIGS, CPS1, ACMSD | KMT2A 1215/4885SMN1; SMN2 4260/4885ANPEP 152/4885 |
| US-20070027210-A1 | Acyloxyalkyl carbamate prodrugs of tranexamic acid, methods of synthesis and use | ACMSD, APEH, CPS1 | KMT2A 1530/4885SMN1; SMN2 3931/4885ANPEP 215/4885 |
| US-20110009483-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | KMT2A 1530/4885SMN1; SMN2 3931/4885ANPEP 215/4885 |
| US-20080153898-A1 | ACYLOXYALKYL CARBAMATE PRODRUGS OF TRANEXAMIC ACID, METHODS OF SYNTHESIS AND USE | ACMSD, APEH, CPS1 | KMT2A 1530/4885SMN1; SMN2 3931/4885ANPEP 215/4885 |
| US-20100036148-A1 | Acyloxyalkyl Carbamate Prodrugs of Tranexamic Acid, Methods of Synthesis and Use | ACMSD, APEH, CPS1 | KMT2A 1530/4885SMN1; SMN2 3931/4885ANPEP 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.